Introduction: The hypertensive double-transgenic (dTG) rat strain, expressing human renin and angiotensinogen, develops severe hypertension and organ damage and 50% of individuals die by 7 weeks of age. Here, we characterise a variation of this model in which animals present stable hypertension.
Materials and methods: The effect of renin—angiotensin system blockers on blood pressure was determined with adult dTG rats treated with enalapril from 3 to 12 weeks of age. Tissue expression levels of renin and angiotensinogen were determined in dTG rats and rhesus monkeys by quantitative PCR.
Results: Upon withdrawal from enalapril, mean arterial pressure (MAP) rose to 160—180 mmHg, with 95% of the female dTG rats surviving for 6 to 12 months, In Sprague-Dawley (SD) rats and rhesus monkeys, renin mRNA was absent or weakly expressed in most tissues, except for the kidneys and adrenals. In dTG rats, human renin expression was high in many additional tissues. The expression of human angiotensinogen in dTG rats followed a similar tissue pattern to SD and rhesus monkey angiotensinogen. Oral dosing of aliskiren, enalapril or losartan provided a similar maximal reduction in MAP and duration of efficacy in telemetrised dTG rats.
Conclusions: Enalapril-pretreated dTG rats are suitable for long-term MAP monitoring and sequential evaluation of human renin inhibitors.
Bohlender J. , Fukamizu A., Lippoldt A., Nomura T., Dietz R., Menard J., et al. High human renin hypertension in transgenic rats. Hypertension1997; 29: 428-434.
2.
Luft FC, Mervaala E., Muller DN, Gross V., Schmidt F., Park JK, et al. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension1999; 33: 212-218.
3.
Mervaala E., Muller DN, Schmidt F., Park JK, Gross V., Bader M., et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension2000 ; 35: 587-594.
4.
Mervaala EM, Muller DN, Park JK, Schmidt F., Lohn M., Breu V., et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension1999; 33: 389-395.
5.
Shagdarsuren E., Wellner M., Braesen JH, Park JK, Fiebeler A., Henke N., et al. Complement activation in angiotensin II-induced organ damage. Circ Res2005; 97: 716-724.
6.
Wellner M., Dechend R., Park JK, Shagdarsuren E., Al Saadi N., Kirsch T., et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics2005 ; 20: 256-267.
7.
Fischer R., Dechend R., Qadri F., Markovic M., Feldt S., Herse F., et al. Dietary n-3 polyunsaturated fatty acids and direct renin inhibition improve electrical remodeling in a model of high human renin hypertension . Hypertension2008; 51: 540-546.
8.
Marki HP, Binggeli A., Bittner B., Bohner-Lang V., Breu V., Bur D., et al. Piperidine renin inhibitors: from leads to drug candidates. Farmaco2001; 56: 21-27.
9.
Dechend R., Shagdarsuren E., Gratze P., Fiebeler A., Pilz B., Meiners S., et al. Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes. J Renin Angiotensin Aldosterone Syst2007; 8: 81-84.
10.
Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend R., Gratze P., et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension2005; 46: 569-576.
11.
Thatcher S. , Yiannikouris F., Gupte M. and Cassis I.The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol2009; 302: 111-117.
12.
Bader M.Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu Rev Pharmacol Toxicol2010; 50: 439-465.
13.
Fischli W., Clozel JP, el Amrani K., Wostl W., Neidhart W., Stadler H., et al. Ro 42-5892 is a potent orally active renin inhibitor in primates . Hypertension1991; 18: 22-31.
14.
Cauchon E., Liu S., Percival MD, Rowland SE, Xu D., Binkert C., et al. Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology. Anal Biochem2009; 388: 134-139.
15.
Bateman KP, Castonguay G., Xu L., Rowland S., Nicoll-Griffith DA, Kelly N., et al. Reduction of animal usage by serial bleeding of mice for pharmacokinetic studies: application of robotic sample preparation and fast liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl2001; 754: 245-251.
16.
Burnham CE, Hawelu-Johnson CL, Frank BM and Lynch KRMolecular cloning of rat renin cDNA and its gene. Proc Natl Acad Sci USA1987; 84: 5605-5609.
17.
Wood JM, Maibaum J., Rahuel J., Grutter MG, Cohen NC, Rasetti V., et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun2003; 308: 698-705.
18.
Mervaala E. , Dehmel B., Gross V., Lippoldt A., Bohlender J., Milia AF, et al. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol1999; 10: 1669-1680.
19.
Ganten D., Wagner J., Zeh K., Bader M., Michel JB, Paul M., et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA1992; 89: 7806-7810.
20.
Feldman DL, Jin L., Xuan H., Contrepas A., Zhou Y., Webb RL, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension2008; 52: 130-136.
21.
Dehmel B., Mervaala E., Lippoldt A., Gross V., Bohlender J., Ganten D., et al. Pressure-natriuresis and -diuresis in transgenic rats harboring both human renin and human angiotensinogen genes. J Am Soc Nephrol1998; 9: 2212-2222.
22.
Weisinger RS , Begg DP and Jois M.Antagonists of the renin-angiotensin system and the prevention of obesity. Curr Opin Investig Drugs2009; 10: 1069-1077.
23.
Stucchi P., Cano V., Ruiz-Gayo M. and Fernandez-Alfonso MSAliskiren reduces body-weight gain, adiposity and plasma leptin during diet-induced obesity. Br J Pharmacol2009; 158: pp. 771-778.
24.
Gratze P., Boschmann M., Dechend R., Qadri F., Malchow J., Graeske S., et al. Energy metabolism in human renin-gene transgenic rats: does renin contribute to obesity?Hypertension2009; 53: 516-523.
25.
Wood JM, Schnell CR, Cumin F., Menard J. and Webb R.l. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens2005; 23: 417-426.
26.
Sealey JE and Laragh JHAliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens2007; 20: 587-597.
27.
Krop M., Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, et al. Aliskiren accumulates in renin secretory granules and binds plasma prorenin. Hypertension2008; 52: 1076-1083.
28.
Krop M. and Danser AHCirculating versus tissue renin-angiotensin system: on the origin of (pro)renin . Curr Hypertens Rep2008; 10: 112-118.
29.
Crowley SD and Coffman TM In hypertension, the kidney breaks your heart. Curr Cardiol Rep2008; 10: 470-476.
